Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 5238SC

5238SC 50 µg (With Carrier)
5238SF 50 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IGF-II (hIGF-II) Ala25-Glu94 (Accession # P01344-2) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIGF-II. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIGF-II does not have a Met on the amino terminus and has a calculated MW of 7,606. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal AYRPS of recombinant hIGF-II was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIGF-II was determined in a cell proliferation assay using primary human dermal fibroblasts. The ED50 of each lot is between 10-20 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIGF-II.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hIGF-II. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IGF-II is a potent cellular mitogen that is closely related to IGF-I (1). IGF-II is primarily produced by the liver and is frequently overexpressed in tumors (1,2). IGF-II binds to the IGF-IR, activating the AKT, mTOR, ERK, and JNK pathways (1). IGF-II signaling is regulated by several distinct mechanisms. First, IGF binding proteins (IGFBPs) bind to IGF-II and block interactions with the IGF-IR (1-3). Second, the IGF-IIR, binds to and acts as a molecular trap for IGF-II (1-3). Lastly, the IGF2 gene is an imprinted gene, and loss of imprinting leads to increased IGF-II levels (1-3). Aberrant levels of IGF-II are associated with Wilms tumor, Beckwith-Wiedmann syndrome, and colorectal cancer (1,2).


1.  Pollak, M. (2008) Nat Rev Cancer 8, 915-28.

2.  Chitnis, M.M. et al. (2008) Clin Cancer Res 14, 6364-70.

3.  Sullivan, K.A. et al. (2008) Endocrinology 149, 5963-71.


Entrez-Gene Id 3481
Swiss-Prot Acc. P01344


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.